Elacestrant in ER+/HER2- mBC: Overview of the EMERALD subgroup analysis

(4:18)

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBC

(5:26)

What’s New for HER2 MBC?

(5:48)

PF-07220060 in HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy

(2:31)

Comprehensive Guide to HER2-Positive Breast Cancer: Stages 1-3 Decoded

(7:26)

Ask the expert: Early-stage HER2-positive breast cancer with Adrienne Waks, MD

(1:5:11)

HER2-positive Breast Cancer - How does it work? A doctor explains with simple images.

(3:11)

HER2-Positive Breast Cancer: A Paradigm Shift in Diagnosis and Therapy

(5:45)

Anti-HER2 Mechanisms of Approved HER2 Inhibitors

(5:5)

HER2-Positive Breast Cancer—Reduce Your Risk of Recurrence | Access Health

(20:11)

HER2 Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019

(53:19)

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and Toxicity

(20:17)

Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast Cancer

(1:24:52)

The Science of HER2-low Breast Cancer and Implications for the Pathology Team

(54:43)

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

(5:1econd)

Exploring novel therapeutic approaches in HR+/ HER2- mBC

(2:6)

Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast Conference

(2:43)

Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms

(30:57)

ELAINE 1: LAS vs fulv in la ER+/HER2- mBC ESR1m + disease progression on AI and CDK4/6i inhibitors

(5:47)

DESTINY-Breast06: determining HER2-(ultra)low status in HR+ mBC

(3:12)

Research Update for HER2-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum Series

(59:33)

Living long term with MBC: Making treatment decisions

(52:22)

Neratinib in MBC with HER2 Activating Mutations

(6:46)

AC versus TaxAC in High-Risk HER2-Negative MBC

(3:13)

HER2+ MBC - Dr. Carey Anders - 2014 MBCN Conference at UNC

(44:15)

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

(3:43)

PF-07220060, a novel oral CDK4-selective inhibitor, in HR+/HER2- mBC

(3:41)

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

(6:38)

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

(4:39)

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

(3:31)